AI Article Synopsis

  • This study assessed the impact of different durations of growth hormone pretreatment on assisted reproductive therapy outcomes in patients with diminished ovarian reserve (DOR), involving a total of 1459 participants.
  • Results indicated that patients receiving GH pretreatment (especially those in the 1-month and 2-month groups) had a significantly higher number of oocytes retrieved compared to a control group without GH treatment.
  • However, extending GH pretreatment beyond 1 month did not yield additional benefits in terms of oocyte retrieval, suggesting that while GH pretreatment is beneficial, longer durations may not be necessary for improved outcomes.

Article Abstract

This study aimed to evaluate the effect of different growth hormone (GH) pretreatment times in assisted reproductive therapy in patients with diminished ovarian reserve (DOR). A retrospective pilot cohort analysis was performed on patients with DOR receiving GH pretreatment in the Assisted Reproduction Unit of Sir Run Run Shaw Hospital. A total of 1459 patients met the criteria and were divided into four groups according to GH pretreatment time as follows: 53 were in the 2-month pretreatment group (GH1), 400 were in the 1-month pretreatment group (GH2), 414 were in the ovulation induction period pretreatment group (GH3), and 592 were in the non-GH pretreatment group (control group). In addition, GH1, GH2, and GH3 were combined in the GH pretreatment group. Baseline characteristics and treatment outcomes were compared between the groups. The number of oocytes retrieved in the GH pretreatment, GH1, GH2, and GH3 groups was significantly higher than that in the control group (all P < .01). The numbers of oocytes retrieved in the GH1 and GH2 groups were similar but were nominally higher than those in the GH3 group. Estradiol concentrations in the GH pretreatment, GH2, and GH3 groups were significantly higher than those in the control group on the day of human chorionic gonadotropin injection (all P < .01). In the GH1 group, 22 patients had >1 assisted reproductive therapy cycle (non-GH pretreatment) before GH pretreatment, and the number of oocytes retrieved in the GH pretreatment cycle was higher than that in the non-GH pretreatment cycle, but this was not significant. These findings suggest that the GH pretreatment time was appropriately prolonged, and the number of oocytes retrieved nominally increased. In patients with DOR, GH pretreatment improved treatment outcomes. More than 1 month of GH pretreatment did not increase the number of oocytes retrieved.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404950PMC
http://dx.doi.org/10.1097/MD.0000000000039645DOI Listing

Publication Analysis

Top Keywords

pretreatment group
20
pretreatment
10
growth hormone
8
hormone pretreatment
8
pretreatment times
8
times assisted
8
assisted reproductive
8
reproductive therapy
8
therapy patients
8
patients diminished
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!